No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BCPC Balchem
- 179.300
- +3.660+2.08%
Trading Jul 23 13:52 ET
5.81BMarket Cap50.65P/E (TTM)
179.740High174.905Low46.29KVolume175.350Open175.640Pre Close8.26MTurnover0.14%Turnover Ratio53.52P/E (Static)32.42MShares179.74052wk High5.39P/B5.77BFloat Cap110.14352wk Low0.79Dividend TTM32.18MShs Float179.740Historical High0.44%Div YieldTTM2.75%Amplitude0.865Historical Low178.367Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Balchem Corporation's (NASDAQ:BCPC) Recent Stock Performance Tethered To Its Strong Fundamentals?
Balchem Corporation (BCPC): Is It Among the Most Profitable Stocks of the Last 20 Years?
Balchem Corporation Announces Quarterly Conference Call for Second Quarter Financial Results on July 26, 2024
Balchem Corporation's (NASDAQ:BCPC) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Top 2 Materials Stocks You May Want To Dump This Month
Balchem Corporation to Present at the CJS Securities 24th Annual New Ideas Summer Conference on July 10, 2024
Comments
Balchem Corporation's market sentiment has improved, as seen in its P/E ratio of 45.01. Despite slower EPS growth, the company's long-term track record and dividends have led to a favorable total shareholder return.
Balchem's (NASDAQ:BCPC) 13% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period 1
The high P/E ratio for Balchem is down to investors foreseeing rapid growth outpacing the market. Despite slight falls, medium-term growth has pleased shareholders. Investors might pay more for the stock expecting strong future growth. This situation could maintain the stock's price.
Balchem's dedication to profit-sharing with shareholders is evident from its three-year median payout ratio of 21%. Yet, an enhancement in its ROE could prove beneficial, given the substantial reinvestment of profits. Expectations suggest an increase in company's earnings, despite its low ROE compared to the industry.
Despite lower-than-average share price increase, the market's consistent positive reception over the past five years suggests worthiness for long-term investments.
Gapping up
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
9
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg